1. Pan SY, Morrison H. Epidemiology of cancer of the small
intestine. World J Gastrointest Oncol. 2011;3:33–42.
2. Orlich MJ, Singh PN, Sabate´ J, et al. Vegetarian dietary patterns
and the risk of colorectal cancers. JAMA Intern Med.
2015;175:767–76.
123
J Gastroenterol (2023) 58:444–457
3. Breekveldt ECH, Lansdorp-Vogelaar I, Toes-Zoutendijk E, et al.
Colorectal cancer incidence, mortality, tumour characteristics,
and treatment before and after introduction of the faecal
immunochemical testing-based screening programme in the
Netherlands: a population-based study. Lancet Gastroenterol
Hepatol. 2022;7:60–8.
4. Wyness L. The role of red meat in the diet: nutrition and health
benefits. Proc Nutr Soc. 2016;75:227–32.
5. Shanware NP, Bray K, Eng CH, et al. Glutamine deprivation
stimulates mTOR-JNK-dependent chemokine secretion. Nat
Commun. 2014;5:4900.
6. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of
amino acids regulates mTOR and autophagy. Cell.
2009;136:521–34.
7. Sun H, Olson KC, Gao C, et al. Catabolic defect of branchedchain amino acids promotes heart failure. Circulation.
2016;133:2038–49.
8. Bi X, Henry CJ. Plasma-free amino acid profiles are predictors of
cancer and diabetes development. Nutr Diabetes. 2017;7: e249.
9. Kanai Y. Amino acid transporter LAT1 (SLC7A5) as a molecular
target for cancer diagnosis and therapeutics. Pharmacol Ther.
2022;230: 107964.
10. Yan R, Zhao X, Lei J, et al. Structure of the human LAT1-4F2hc
heteromeric amino acid transporter complex. Nature.
2019;568:127–30.
11. Cormerais Y, Giuliano S, LeFloch R, et al. Genetic disruption of
the multifunctional CD98/LAT1 complex demonstrates the key
role of essential amino acid transport in the control of mTORC1
and tumor growth. Cancer Res. 2016;76:4481–92.
12. Yanagida O, Kanai Y, Chairoungdua A, et al. Human L-type
amino acid transporter 1 (LAT1): characterization of function and
expression in tumor cell lines. Biochim Biophys Acta.
2001;1514:291–302.
13. Boado RJ, Li JY, Nagaya M, et al. Selective expression of the
large neutral amino acid transporter at the blood-brain barrier.
Proc Natl Acad Sci USA. 1999;96:12079–84.
14. Kaira K, Sunose Y, Arakawa K, et al. Prognostic significance of
L-type amino-acid transporter 1 expression in surgically resected
pancreatic cancer. Br J Cancer. 2012;107:632–8.
15. Furuya M, Horiguchi J, Nakajima H, et al. Correlation of L-type
amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103:382–9.
16. Takeuchi K, Ogata S, Nakanishi K, et al. LAT1 expression in
non-small-cell lung carcinomas: analyses by semiquantitative
reverse transcription-PCR (237 cases) and immunohistochemistry
(295 cases). Lung Cancer. 2010;68:58–65.
17. Sakata T, Hana K, Mikami T, et al. Positive correlation of
expression of L-type amino-acid transporter 1 with colorectal
tumor progression and prognosis: higher expression in sporadic
colorectal tumors compared with ulcerative colitis-associated
neoplasia. Pathol Res Pract. 2020;216: 152972.
18. Preston SL, Leedham SJ, Oukrif D, et al. The development of
duodenal microadenomas in FAP patients: the human correlate of
the min mouse. J Pathol. 2008;214:294–301.
19. Quan L, Ohgaki R, Hara S, et al. Amino acid transporter LAT1 in
tumor-associated vascular endothelium promotes angiogenesis by
regulating cell proliferation and VEGF-A-dependent mTORC1
activation. J Exp Clin Cancer Res. 2020;39:266.
20. Abremski K, Hoess R. Bacteriophage P1 site-specific recombination. Purification and properties of the Cre recombinase protein. J Biol Chem. 1984;259:1509–14.
21. Ohgaki R, Ohmori T, Hara S, et al. Essential roles of L-type
amino acid transporter 1 in syncytiotrophoblast development by
presenting fusogenic 4F2hc. Mol Cell Biol. 2017;37:e00427e516.
J Gastroenterol (2023) 58:444–457
22. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the
cells-of-origin of intestinal cancer. Nature. 2009;457:608–11.
23. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal
integration to cancer, diabetes and ageing. Nat Rev Mol Cell
Biol. 2011;12:21–35.
24. Liu GY, Sabatini DM. Mtor at the nexus of nutrition, growth,
ageing and disease. Nat Rev Mol Cell Biol. 2020;21:183–203.
25. Alao JP. The regulation of cyclin D1 degradation: roles in cancer
development and the potential for therapeutic invention. Mol
Cancer. 2007;6:24.
26. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling:
components, mechanisms, and diseases. Dev Cell. 2009;17:9–26.
27. Rad E, Murray JT, Tee AR. Oncogenic signalling through
mechanistic target of rapamycin (mTOR): a driver of metabolic
transformation and cancer progression. Cancers (Basel).
2018;10:5.
28. Thoreen CC. The molecular basis of mTORC1-regulated translation. Biochem Soc Trans. 2017;45:213–21.
29. Thoreen CC, Chantranupong L, Keys HR, et al. A unifying model
for mTORC1-mediated regulation of mRNA translation. Nature.
2012;485:109–13.
30. Faller WJ, Jackson TJ, Knight JR, et al. mTORC1-mediated
translational elongation limits intestinal tumour initiation and
growth. Nature. 2015;517:497–500.
31. Kim C, Kim B. Anti-cancer natural products and their bioactive
compounds inducing ER stress-mediated apoptosis: a review.
Nutrients. 2018;10:1021.
32. Xu K, Han B, Bai Y, et al. MiR-451a suppressing BAP31 can
inhibit proliferation and increase apoptosis through inducing ER
stress in colorectal cancer. Cell Death Dis. 2019;10:152.
33. Zhang J, Xu Y, Li D, et al. Review of the correlation of LAT1
with diseases: mechanism and treatment. Front Chem. 2020;8:
564809.
34. Walsh JG, Cullen SP, Sheridan C, et al. Executioner caspase-3
and caspase-7 are functionally distinct proteases. Proc Natl Acad
Sci USA. 2008;105:12815–9.
35. Kitamura H, Ohno Y, Toyoshima Y, et al. Interleukin-6/STAT3
signaling as a promising target to improve the efficacy of cancer
immunotherapy. Cancer Sci. 2017;108:1947–52.
36. Huber S, Gagliani N, Zenewicz LA, et al. IL-22BP is regulated
by the inflammasome and modulates tumorigenesis in the intestine. Nature. 2012;491:259–63.
37. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha
in mice reduces colorectal carcinogenesis associated with chronic
colitis. J Clin Investing. 2008;118:560–70.
457
38. Benito I, Encı´o IJ, Milagro FI, et al. Microencapsulated bifidobacterium bifidum and lactobacillus gasseri in combination
with quercetin inhibit colorectal cancer development in Apc(Min/
) mice. Int J Mol Sci. 2021;22:4906.
39. Bevins CL, Salzman NH. Paneth cells, antimicrobial peptides and
maintenance of intestinal homeostasis. Nat Rev Microbiol.
2011;9:356–68.
40. Sato T, van Es JH, Snippert HJ, et al. Paneth cells constitute the
niche for Lgr5 stem cells in intestinal crypts. Nature.
2011;469:415–8.
41. Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build
crypt-villus structures in vitro without a mesenchymal niche.
Nature. 2009;459:262–5.
42. van der Flier LG, Haegebarth A, Stange DE, et al. OLFM4 is a
robust marker for stem cells in human intestine and marks a
subset of colorectal cancer cells. Gastroenterology.
2009;137:15–7.
43. Chen Q, Suzuki K, Sifuentes-Dominguez L, et al. Paneth cellderived growth factors support tumorigenesis in the small intestine. Life Sci Alliance. 2021;4: e202000934.
44. Farin HF, Van Es JH, Clevers H. Redundant sources of Wnt
regulate intestinal stem cells and promote formation of Paneth
cells. Gastroenterology. 2012;143:1518-29.e7.
45. Jewell JL, Russell RC, Guan KL. Amino acid signalling upstream
of mTOR. Nat Rev Mol Cell Biol. 2013;14:133–9.
46. Oshima M, Oshima H, Kitagawa K, et al. Loss of Apc
heterozygosity and abnormal tissue building in nascent intestinal
polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci
USA. 1995;92:4482–6.
47. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and selfkilling: crosstalk between autophagy and apoptosis. Nat Rev Mol
Cell Biol. 2007;8:741–52.
48. Najumudeen AK, Ceteci F, Fey SK, et al. The amino acid
transporter SLC7A5 is required for efficient growth of KRASmutant colorectal cancer. Nat Genet. 2021;53:16–26.
49. Kandasamy P, Gyimesi G, Kanai Y, et al. Amino acid transporters revisited: new views in health and disease. Trends Biochem Sci. 2018;43:752–89.
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
123
...
論文の公開元へ
